SOURCES:
Peter Hotez, MD, PhD, dean, Nationwide College of Tropical Drugs, Baylor School of Drugs; co-director, Middle for Vaccine Building, Texas Youngsters’s Sanatorium, Houston.
Paul Offit, MD, director, Vaccine Schooling Middle and professor of pediatrics, Youngsters’s Sanatorium of Philadelphia.
Michael T. Osterholm, PhD, director, Middle for Infectious Illness Analysis and Coverage (CIDRAP), College of Minnesota, Minneapolis.
Floor Truths. Eric Topol, MD: “The bivalent vaccine booster outperforms.”
CDC: “COVID Information Tracker: Weekly Evaluation,” “Charges of Laboratory-Showed COVID-19 Hospitalizations by way of Vaccination Standing,” “Development within the Choice of COVID-19 Vaccinations within the U.S.”
FDA: “Vaccine and Comparable Organic Merchandise Advisory Committee January 26 Assembly Announcement.”
The New England Magazine of Drugs: “Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters,” “Antibody Reaction to Omicron BA.4-BA.5 Bivalent Booster,” “Neutralization in opposition to BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster,” “Bivalent Covid-19 Vaccines – A Cautionary Story.”
Nature Drugs: “Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by way of parental mRNA vaccine or a BA.5 bivalent booster.”
BioRxiv: “Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants,” “Advanced Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine.”
Kaiser Circle of relatives Basis: “ How A lot May COVID-19 Vaccines Price the U.S. After Commercialization?”
Alison Chartan, spokesperson, Novavax.
Pfizer Media Members of the family.
